Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey
Findings from a longitudinal qualitative study
Dados Bibliográficos
| ID | 14908994 |
|---|---|
| Autores | Parkin (0000-0003-1621-0945, King's College London, autor correspondente), Joanne Neale (0000-0003-1502-5983, King's College London), John Strang (0000-0001-9142-210X) |
| Ano | 2023 |
| Volume | 122 |
| Páginas | 104221 |
| Data de publicação | 2023-12-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | International Journal of Drug Policy (JOURNAL) |
| Identificadores do periódico | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Editora | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2023.104221 |
| PMID | 37865052 |
| OpenAlex | W4387793167 |
| Idioma | EN |
| Citações recebidas | 11 |
| Referências citadas | 39 |
Retention in treatment for OUD with LAIB, for at least 12-months, can be conceptualised as a journey. This conceptualisation emphasises the benefits (and challenges) clinicians and patients may expect to encounter during the first year of a LAIB treatment programme. An added implication of conceptualising LAIB treatment in this manner is that optimal benefits of the medication (as observed by participants) began to emerge during 'months 7-12' of the retention journey
Buprenorphine · Narrative · Opioid · Opioid use disorder · Psychiatry · Psychotherapist · Qualitative research · Sociology · Thematic analysis · Clinical Psychology · Medicine · Mental Health and Patient Involvement · Nursing · Opioid Use Disorder Treatment · Psychology · Substance Abuse Treatment and Outcomes
Long-Acting Injectable Buprenorphine for Opioid Use Disorder
Patient satisfaction with long-acting injectable buprenorphine
Making long‐acting treatment work
The matter of mattering in depot buprenorphine treatment
The benefits and potential biases of lived experience in substance use treatment services
Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence
The impact of medications for opioid use disorder (Moud) on retention and recovery capital in recovery housing
Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine
The ‘knowing’ body in the becoming of buprenorphine depot treatment
Risk of drug-related mortality among people receiving opioid-agonist treatment during the Covid-19 pandemic in Scotland
Regimes of Drug Desires
Understanding Customer Experience Throughout the Customer Journey
The Wounded Storyteller
Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder
Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder
Comparing three stages of addiction recovery
Can a new formulation of opiate agonist treatment alter stigma
My Journey Map”
The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence
In search of how people change
Addicts' narratives of recovery from drug use
What are tests for? The implications of stuttering steps along the US patient pathway
Signposts on the journey'; medication adherence and the lived body in men with Parkinson's disease
Longitudinal Qualitative Research
Team ethnography visual maps
| Obras citantes distintas | 11 |
|---|---|
| Citações por ano | 5,5 |
| Intervalo de citações | 2024 - 2026 (3) |
| Velocidade de citação | current |
| Altamente citado | Não |
| Tipos de citação | Neutras: 11 |